Vaxelis

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IA/0046	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	23/01/2019	n/a		
IB/0045	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	14/01/2019		SmPC and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

IAIN/0044/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/12/2018	n/a		
IA/0043	B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised	12/12/2018	n/a		
II/0040	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	08/11/2018	n/a		
IB/0041	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	10/10/2018	n/a		
IB/0039/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	06/09/2018	n/a		

	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
PSUSA/10469 /201802	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	06/09/2018	n/a		PRAC Recommendation - maintenance
IB/0038	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	05/09/2018	n/a		
IB/0037	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	26/06/2018	n/a		
IB/0036/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	26/06/2018	n/a		
II/0030	B.I.z - Quality change - Active substance - Other variation	31/05/2018	n/a		

IB/0034	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/05/2018	n/a		
IB/0033	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/05/2018	n/a		
IB/0032/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/05/2018	n/a		
IA/0031/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting	02/05/2018	n/a		

	material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/04/2018		PL	
II/0026	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	15/03/2018	n/a		
PSUSA/10469 /201708	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	08/03/2018	n/a		PRAC Recommendation - maintenance
IB/0028/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.z - Change in the specification parameters	26/02/2018	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Other variation				
IB/0025/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	22/01/2018	n/a		
IB/0023	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	11/01/2018	n/a		
II/0021	Update of section 5.1 of the SmPC in order to update the efficacy section on immune persistence based on the final results from study PRI03C - Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5-year-old Children Previously Vaccinated with a 2 dose or 3 dose Infants Series and Toddler dose of Vaxelis or INFANRIX hexa listed as P46 study in the PIP. The RMP version 2.2 has also been submitted. In addition, the MAH took the opportunity to	11/01/2018	15/03/2018	SmPC and Labelling	The SmPC section 5.1 has been updated following the completion of PRI03C study with the data on long- term immune persistence following the vaccination with Vaxelis. The purpose of this study was to provide the results of the long-term persistence of anti-Hepatitis B surface antigen (antiHBsAg) and pertussis antibody (PT, FHA, PRN and FIM) responses in children previously vaccinated with Vaxelis or Infanrix hexa. The data was collected 3 to 4 years after completion of a 2+1 or 3+1 vaccination schedule. The proportion of children seroprotected (anti-HBsAg ≥10

	introduce editorial changes in Annex IIIA. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				mIU/mL – accepted correlate of protection) after those vaccination schedules decreased by approximately 30% in approximately 4 years. Considerable study data suggest that individuals who have ever had a seroprotective response to HB vaccination will have a memory response that is protective against clinical disease if exposed to the HB virus. The immunogenicity findings also support the long-term persistence of pertussis antibody responses. After approximately 4 years, the percentages of children with anti-pertussis antibodies above Lower Limit of Quantification (LLOQ) were as follows: anti-PT 58.4%, anti-FHA 80.9%, anti-PRN 66.1% and anti-FIM 94.3%. Clinical data had confirmed that Vaxelis is comparable to currently licensed vaccine controls with respect to immunogenicity and safety, when given concomitantly with other licensed routine paediatric vaccines.
IB/0027	B.II.d.2.z - Change in test procedure for the finished product - Other variation	20/12/2017	n/a		
IB/0024	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	06/12/2017	n/a		
PSUSA/10469 /201702	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	28/09/2017	n/a		PRAC Recommendation - maintenance
IA/0020	B.I.b.1.c - Change in the specification parameters	22/09/2017	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method				
IB/0019	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	15/08/2017	n/a		
IB/0017/G	This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation	10/08/2017	n/a		
IB/0018	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	09/08/2017	n/a		
IB/0015	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	21/07/2017	n/a		
II/0012/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the	20/07/2017	n/a		

	manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.III.2.a.2 - Change of specification(s) of a former				

	non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material				
N/0016	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/07/2017	15/03/2018	Labelling and PL	
IB/0013/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.1.z - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Other variation B.III.1.z - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Other variation	09/06/2017	n/a		
IB/0011	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	08/06/2017	n/a		
IB/0010	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	26/04/2017	n/a		

IB/0009	B.I.z - Quality change - Active substance - Other variation	06/04/2017	n/a		
IAIN/0008	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	16/03/2017	15/03/2018	Annex II and PL	
PSUSA/10469 /201608	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	09/03/2017	n/a		PRAC Recommendation - maintenance
T/0007	Transfer of Marketing Authorisation from Sanofi Pasteur MSD SNC to MCM Vaccine B.V. Transfer of Marketing Authorisation	19/12/2016	27/01/2017	SmPC, Labelling and PL	
IB/0005	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	24/10/2016	n/a		
IA/0004/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters	19/10/2016	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IA/0003	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	19/10/2016	n/a		
II/0002	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	15/09/2016	n/a		
IAIN/0001/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	25/05/2016	27/01/2017	Annex II and PL	